LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Spin Column-Based Kits for Standardized Extraction of Exosome RNA

By LabMedica International staff writers
Posted on 21 Sep 2015
Print article
exoRNeasy Serum/Plasma Kits for efficient purification of RNA from exosomes and other extracellular vesicles in serum or plasma samples
exoRNeasy Serum/Plasma Kits for efficient purification of RNA from exosomes and other extracellular vesicles in serum or plasma samples (Photo courtesy of QIAGEN)
A novel spin column-based method has been developed that provides a faster, more reliable means for the isolation of RNA from exosomes for research, delivering high-quality results with less labor-intensive sample preparation.

Exosomes and other extracellular vesicles (commonly referred to as EVs) have generated considerable attention for their potential applications in both diagnostics and therapeutics. The contents of these vesicles are the subject of intense research, and the relatively recent discovery of RNA inside EVs has raised interest in the biological function of these RNAs as well as their potential as biomarkers for cancer and other diseases. Traditional ultracentrifugation-based protocols to isolate EVs are labor-intensive and subject to significant variability.

The traditional ultracentrifugation method for isolating EV RNA is now being superseded by a series of spin column-based extraction kits developed by QIAGEN (Venlo, The Netherlands) in conjunction with Exosome Diagnostics, Inc. (Cambridge, MA, USA) and marketed by QIAGEN under the name exoEasy (for whole EV isolation) and exoRNeasy (for extraction of EV RNA).

Use of the exoRNeasy kit was described in a paper in the August 28, 2015, online edition of the journal PLOS ONE that was authored by investigators from QIAGEN and Exosome Diagnostics. Briefly, pre-filtered plasma was mixed with binding buffer and added to the exoEasy membrane affinity column to bind the EVs to the membrane. After centrifugation, the flow-through was discarded, and wash buffer was added to the column to remove nonspecifically retained material. After another centrifugation and discarding of the flow-through, the vesicles were lysed by adding QIAzol to the spin column, and the lysate was collected by centrifugation. The miRNeasy Serum/Plasma Spike-In Control was added. Following addition of chloroform, thorough mixing, and centrifugation to separate organic and aqueous phases, the aqueous phase was recovered and mixed with ethanol. The sample-ethanol mixture was added to an RNeasy MinElute spin column and centrifuged. The column was washed three times with buffer followed by elution of RNA in water. This procedure allowed concentrating the extracellular RNA from four milliliters of plasma or serum into a final volume of 14 microliters of water. This method was an improvement over traditional methods in providing a faster, more standardized way to achieve reliable high quality RNA preparations from EVs in serum and plasma.

“The QIAGEN exoRNeasy Maxi Kit standardized protocol, developed in partnership with Exosome Diagnostics, Inc., is the most sophisticated method for the extraction of RNA from exosomes,” said contributing author Dr. Markus Sprenger-Haussels, head of the sample technologies unit at QIAGEN. “The study also reinforces QIAGEN’s leadership for sample technologies which are paving the way for the growing acceptance of liquid biopsies. QIAGEN provides a range of novel sample technologies for liquid biopsies to help gain valuable molecular insights from easily collected samples of blood or other liquids.”

“As the world leader in sample preparation, QIAGEN's partnership with Exosome Diagnostics is accelerating the pace at which researchers and drug developers across the globe are utilizing exosomes from biofluids. Exosomes provide a powerful molecular research approach that is getting significant attention given its many advantages over tissue-based approaches," said Dr. Johan Skog, CSO of Exosome Diagnostics. “Our ongoing collaboration with QIAGEN and these important new data provide further validation that Exosome Diagnostics' technology offers a highly sensitive and reproducible method to isolate and extract nucleic acid from exosomes for routine laboratory use.”

Related Links:

QIAGEN
Exosome Diagnostics, Inc.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more